54 related articles for article (PubMed ID: 38430660)
1. Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.
Lv X; Guo L; Wang C
J Gynecol Oncol; 2024 May; 35(3):e27. PubMed ID: 38216133
[TBL] [Abstract][Full Text] [Related]
2. Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia.
Chen J; Cao D; Yang J; Yu M; Zhou H; Cheng N; Wang J; Zhang Y; Peng P; Shen K
Int J Gynecol Cancer; 2022 Dec; 32(12):1561-1567. PubMed ID: 36368706
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
Kim NK; Choi CH; Seong SJ; Lee JM; Lee B; Kim K
Gynecol Oncol; 2024 Apr; 183():68-73. PubMed ID: 38520881
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy and obstetric outcomes after fertility-sparing management of endometrial cancer and atypical hyperplasia: a multicentre cohort study.
Vasileva R; Wohrer H; Gaultier V; Bucau M; Courcier H; Ben Miled S; Gonthier C; Koskas M
Hum Reprod; 2024 Jun; 39(6):1231-1238. PubMed ID: 38719783
[TBL] [Abstract][Full Text] [Related]
5. A survey of French gynecologists' knowledge and attitudes toward conservative treatment for fertility preservation in young patients with endometrial cancer.
Peigné M; Maumy L; Koskas M
J Gynecol Obstet Hum Reprod; 2020 Sep; 49(7):101794. PubMed ID: 32416273
[TBL] [Abstract][Full Text] [Related]
6. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer.
Brown AJ; Westin SN; Broaddus RR; Schmeler K
Obstet Gynecol; 2012 Feb; 119(2 Pt 2):423-426. PubMed ID: 22270425
[TBL] [Abstract][Full Text] [Related]
7. Updates on conservative management of endometrial cancer in patients younger than 45 years.
Lucchini SM; Esteban A; Nigra MA; Palacios AT; Alzate-Granados JP; Borla HF
Gynecol Oncol; 2021 Jun; 161(3):802-809. PubMed ID: 33892887
[TBL] [Abstract][Full Text] [Related]
8. Oocyte collection and outcome following oncologic treatment: a retrospective multicentre study.
Fernández-González MJ; Borgmann-Staudt A; Llagostera CG; Ceballos-Garcia E; Gebauer J; Jantke A; Barnbrock A; Kentenich H; Klco-Brosius S; Lotz L; Balcerek M
Support Care Cancer; 2024 May; 32(6):390. PubMed ID: 38806697
[TBL] [Abstract][Full Text] [Related]
9. Metformin and progestins in women with atypical hyperplasia or endometrial cancer: systematic review and meta-analysis.
Adamyan L; Pivazyan L; Isaeva S; Shapovalenko R; Zakaryan A
Arch Gynecol Obstet; 2024 Jun; 309(6):2289-2305. PubMed ID: 38503850
[TBL] [Abstract][Full Text] [Related]
10. Current practice with operative hysteroscopy for fertility preservation in endometrial cancer and endometrial premalignancies.
Bilir E; Kacperczyk-Bartnik J; Bizzarri N; Kahramanoğlu İ
Arch Gynecol Obstet; 2024 Jun; 309(6):2267-2278. PubMed ID: 38493419
[TBL] [Abstract][Full Text] [Related]
11. DEAR model in overweight endometrial cancer patients undergoing fertility-sparing treatment: A randomized controlled trial.
Chen Y; Yang J; Wan Y; Li Q; Yang D; Wang Y; Gong J; Bai L; Liu Y; Li X; Wang J
Gynecol Oncol; 2024 Jun; 185():148-155. PubMed ID: 38422947
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia: Japanese Gynecologic Oncology Group study (JGOG2051/KGOG2031, REMPA trial).
Sakai K; Yamagami W; Sato Y; Susumu N; Yokoyama Y; Takehara K; Mandai M; Okamoto A
J Gynecol Oncol; 2024 May; ():. PubMed ID: 38789396
[TBL] [Abstract][Full Text] [Related]
13. Fertility-preservation in endometrial cancer: is it safe? Review of the literature.
Carneiro MM; Lamaita RM; Ferreira MC; Silva-Filho AL
JBRA Assist Reprod; 2016 Dec; 20(4):232-239. PubMed ID: 28050959
[TBL] [Abstract][Full Text] [Related]
14. Patient Location and Disparities in Access to Fertility Preservation for Women With Gynecologic or Breast Cancer.
Kanbergs A; Jorgensen K; Agusti N; Viveros-Carreño D; Wu CF; Nitecki R; Harris JA; Woodard T; Ramphul R; Rauh-Hain JA
Obstet Gynecol; 2024 Jun; 143(6):824-834. PubMed ID: 38574368
[TBL] [Abstract][Full Text] [Related]
15. Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy.
Azim HA; Niman SM; Partridge AH; Demeestere I; Ruggeri M; Colleoni M; Saura C; Shimizu C; Saetersdal AB; Kroep JR; Mailliez A; Warner E; Borges VF; Amant F; Gombos A; Kataoka A; Rousset-Jablonski C; Borstnar S; Takei J; Lee JE; Walshe JM; Ruíz-Borrego M; Moore HCF; Saunders C; Bjelic-Radisic V; Susnjar S; Cardoso F; Klar NJ; Spanic T; Ruddy K; Piccart M; Korde LA; Goldhirsch A; Gelber RD; Pagani O; Peccatori FA
J Clin Oncol; 2024 May; ():JCO2302292. PubMed ID: 38810178
[TBL] [Abstract][Full Text] [Related]
16. Assessing ovarian stimulation with letrozole and levonorgestrel intrauterine system after combined fertility-sparing approach for atypical endometrial lesions: a retrospective case-control study.
Gallo A; Di Spiezio Sardo A; Conforti A; Iorio GG; Zizolfi B; Buonfantino C; De Angelis MC; Strina I; Marrone V; Bifulco G; Alviggi C
Reprod Biomed Online; 2024 May; 48(5):103750. PubMed ID: 38430660
[TBL] [Abstract][Full Text] [Related]
17. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
18. Impact of letrozole co-treatment during ovarian stimulation on oocyte yield, embryo development, and live birth rate in women with normal ovarian reserve: secondary outcomes from the RIOT trial.
Bülow NS; Warzecha AK; Nielsen MV; Andersen CY; Holt MD; Petersen MR; Sopa N; Zedeler A; Englund AL; Pinborg A; Grøndahl ML; Skouby SO; Macklon NS
Hum Reprod; 2023 Nov; 38(11):2154-2165. PubMed ID: 37699851
[TBL] [Abstract][Full Text] [Related]
19. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
